CLU (Clusterin)

Our findings define a distinct immune signature in refractory MG, identify potential biomarkers of treatment resistance, and highlight plasma cell depletion, IL-6 or complement inhibition, and Treg expansion as promising therapeutic avenues.

These findings highlight that both AD-MSCs and their exosomes confer significant therapeutic effect against CTX-induced hepatorenal toxicity through modulation of apoptosis, inflammation, and oxidative stress pathways. Importantly, AD-MSCs-Exos demonstrated superior therapeutic efficacy compared to AD-MSCs in restoring antioxidant defenses and attenuating inflammatory and apoptotic responses in both liver and kidney tissues.

FDCS is a rare neoplasm with variable morphologic and staining patterns. To the best of our knowledge, this is the first reported instance of pleura-based FDCS with epithelioid morphology and aberrant expression of cytokeratins. Diagnosis of such cases can be challenging, which has to be separated from the morphologic mimicries, particularly carcinoma and mesothelioma.

Using both ante-mortem and post-mortem indicators of CAA, several candidate plasma biomarkers of CAA have been found, whereas replications in bigger samples with multiple measurements are crucial to address confounder factors and temporal relationships.

P=N/A, N=30, Active, not recruiting, Children's Hospital of Orange County | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Oct 2024 --> Jun 2026

This study introduces a novel class of sCLU-enhancing compounds, highlighting a promising strategy to mitigate AD pathology. DDL-357 shows potential to address primary drivers of AD while supporting neuroprotective mechanisms and improving memory in AD models. These findings support further development of DDL-357, with future studies potentially including larger preclinical cohorts, expansion to rat models, and additional biomarker analysis.

The potential for increased debris clearance mediated by clusterin and availability of oligodendrocyte progenitors in females may indicate an environment more primed for repair, potentially including remyelination. This could contribute to the disparity in etiology in females versus males.

This study comprehensively mapped PRGs in PTC, established a validated risk model, and provided insights into immune-microenvironment interactions and therapeutic targets, advancing precision oncology for PTC.

CLU-mediated regulation of apoptosis and invasion pathways emerges as a critical mechanism in HCC progression according to our data. Our findings demonstrated that CLU is a promising therapeutic target for HCV-associated HCC, providing novel perspectives for developing targeted treatments against this aggressive cancer.

Bryodulcosigenin exerted anti-inflammatory and neuroprotective effects against CIR injury via alteration of TLR4/NF-κB signaling pathways.

This similarity underscores the reliability of this multicolor single-cell imaging technique for detecting cadmium-induced CSCs in spheroids. Overall, this study demonstrates that intact single-cell imaging of 3D bioprinted tumor spheroids is a powerful tool for illustrating the risk of developing drug-resistant CSCs upon exposure to carcinogens such as cadmium.

Isofraxidin treatment exhibited brain protective against cerebral ischemia reperfusion via suppression of free radical and inflammatory reaction.